First-line Nivolumab Plus Ipilimumab is Safe and Provides Encouraging Survival in Patients with Advanced NSCLC and Co-Morbidity or Poor Performance Status
Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
Pembrolizumab May Be Considered as a First-Line Treatment Option in Non-Squamous NSCLC Even in the Presence of KRAS Mutations
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer
A Daratumumab-Based Combination Shows a Significant Improvement in Overall Survival in Newly Diagnosed Multiple Myeloma
The results from the ALCYONE study
FDA Approves Atezolizumab With Nab-paclitaxel and Carboplatin for Metastatic Non-squamous NSCLC Without EGFR/ALK Aberrations
Evidence for efficacy is based on the results from the IMpower130 study
Cervical Cancer Ranked in the Top Three Cancers Affecting Women Younger Than 45 Years
It is a major public health problem particularly in less-resourced countries
FDA Approves Crizanlizumab-tmca and Voxelotor for Sickle Cell Disease
Evidence for efficacy for crizanlizumab-tmca is based on the results from the SUSTAIN trial and for voxelotor on the results from the HOPE study
Weekly Dose-Dense Chemotherapy Does Not Improve PFS in First-Line Treatment for Epithelial Ovarian Cancer
ICON8 results show no improvement in progression-free survival compared with standard 3-weekly regimen in predominantly European population
Fostamatinib Received a Positive Opinion from the EMA for the Treatment of Primary Immune Thrombocytopenia
Fostamatinib blocks spleen tyrosine kinase.
People with Mental Illness Receive Less Cancer Screening
Findings from the systematic review and comparative meta-analysis
Randomised Trial of Supplemental MRI Screening in Women with Extremely Dense Breast Tissue
The results from the DENSE study
EMA Recommends Granting a Conditional Marketing Authorisation for Polatuzumab Vedotin
It is intended for the treatment of relapsed/refractory DLBCL in combination with bendamustine and rituximab
First-line Treatment with Osimertinib Associated with Longer OS in EGFR Mutation–positive Advanced NSCLC
Osimertinib provides longer overall survival than a comparator EGFR tyrosine kinase inhibitor in EGFR mutation–positive, advanced non-small cell lung cancer